Fujifilm Biotechnologies has opened its $3.2- billion commercial-scale cell-culture biomanufacturing site in Holly Springs, North Carolina.  

The first phase of the planned $3.2-billion manufacturing site opens with a capacity of 8 x 20,000-L mammalian cell-culture bioreactors to encompass drug-product and drug-substance manufacturing while adding finished goods capabilities in 2026. The second-phase expansion (announced in 2024) will double capacity with an additional 8 x 20,000-L bioreactors for a total of 16 bioreactors. 

The new facility currently employs over 680 employees and is on track to reach 750 employees by the end of the year (2025), with an overall goal of hiring a total of 1,400 employees by 2031. Fujifilm Biotechnologies has nearly 5,000 employees worldwide. 

Source: Fujifilm Biotechnologies